We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Albemarle (ALB) Tops Earnings, Revenue Estimates in Q4
Read MoreHide Full Article
Albemarle Corporation (ALB - Free Report) recorded a profit of $602.1 million or $5.30 per share for the fourth quarter of 2016, a more than three-fold rise from a profit of $174.3 million or $1.55 per share registered a year ago.
The results in the reported quarter include $546.3 million in after-tax gains associated with the sale of the Chemetall Surface Treatment business. Albemarle, in late 2016, completed the sale of the Chemetall Surface Treatment unit to German chemical giant BASF for around $3.1 billion.
Barring one-time items, adjusted earnings for the reported quarter were 78 cents per share, topping the Zacks Consensus Estimate of 75 cents.
Revenues fell around 4% year over year to $696.7 million in the reported quarter. Sales fell in the quarter as higher sales volumes, favorable price and mix impacts in certain businesses and favorable currency impact were more than offset by divestitures of the company’s metal sulfides and minerals-based flame retardants and specialty chemicals businesses. However, sales beat the Zacks Consensus Estimate of $599.8 million.
Albemarle Corporation Price, Consensus and EPS Surprise
The company’s former Performance Chemicals segment has been split into two separate reportable segments – Lithium and Advanced Materials and Bromine Specialties.
Sales from the Lithium and Advanced Materials unit jumped 30% year over year to $278.3 million in the reported quarter, supported by favorable currency and pricing impacts and higher sales volumes.
The Bromine Specialties segment raked in sales of $194.5 million, up roughly 13% year over year, aided by favorable currency swings and higher sales volumes.
Revenues from the Refining Solutions unit was $193.1 million in the reported quarter, down around 4% year over year. Sales were affected by unfavorable currency and pricing impacts as well as lower sales volumes.
Financial Position
Albemarle ended 2016 with cash and cash equivalents of roughly $2.3 billion, a more than ten-fold year over year increase. Long-term debt was $2.1 billion, down 32% year over year. Cash flow from operations were around $733.4 million for 2016, up 103% year over year.
Outlook
Moving ahead, the company noted that its performance in 2016 and strategic initiatives have positioned it for strong growth in 2017. Albemarle sees net sales in the band of $2.8 billion to $2.95 billion and adjusted earnings per share of between $4.00 and $4.25 for 2017. Adjusted EBITDA for the year is expected to be between $800 million and $840 million.
Price Performance
Albemarle’s shares have gained 64.4% over a year, outperforming the Zacks categorized Chemicals-Diversified industry’s gain of 28.5% over the same period, partly reflecting its forecast-topping earnings performance over the trailing four quarters.
Celanese has an expected long-term growth of 8.8%.
Cabot has an expected long-term growth of 12.1%.
Chemours has an expected long-term growth of 15.5%.
A Full-Blown Technological Breakthrough in the Making
Zacks’ Aggressive Growth Strategist Brian Bolan explores autonomous cars in our latest Special Report, Driverless Cars: Your Roadmap to Mega-Profits Today. In addition to who will be selling them and how the auto industry will be impacted, Brian reveals 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Albemarle (ALB) Tops Earnings, Revenue Estimates in Q4
Albemarle Corporation (ALB - Free Report) recorded a profit of $602.1 million or $5.30 per share for the fourth quarter of 2016, a more than three-fold rise from a profit of $174.3 million or $1.55 per share registered a year ago.
The results in the reported quarter include $546.3 million in after-tax gains associated with the sale of the Chemetall Surface Treatment business. Albemarle, in late 2016, completed the sale of the Chemetall Surface Treatment unit to German chemical giant BASF for around $3.1 billion.
Barring one-time items, adjusted earnings for the reported quarter were 78 cents per share, topping the Zacks Consensus Estimate of 75 cents.
Revenues fell around 4% year over year to $696.7 million in the reported quarter. Sales fell in the quarter as higher sales volumes, favorable price and mix impacts in certain businesses and favorable currency impact were more than offset by divestitures of the company’s metal sulfides and minerals-based flame retardants and specialty chemicals businesses. However, sales beat the Zacks Consensus Estimate of $599.8 million.
Albemarle Corporation Price, Consensus and EPS Surprise
Albemarle Corporation Price, Consensus and EPS Surprise | Albemarle Corporation Quote
Segment Highlights
The company’s former Performance Chemicals segment has been split into two separate reportable segments – Lithium and Advanced Materials and Bromine Specialties.
Sales from the Lithium and Advanced Materials unit jumped 30% year over year to $278.3 million in the reported quarter, supported by favorable currency and pricing impacts and higher sales volumes.
The Bromine Specialties segment raked in sales of $194.5 million, up roughly 13% year over year, aided by favorable currency swings and higher sales volumes.
Revenues from the Refining Solutions unit was $193.1 million in the reported quarter, down around 4% year over year. Sales were affected by unfavorable currency and pricing impacts as well as lower sales volumes.
Financial Position
Albemarle ended 2016 with cash and cash equivalents of roughly $2.3 billion, a more than ten-fold year over year increase. Long-term debt was $2.1 billion, down 32% year over year. Cash flow from operations were around $733.4 million for 2016, up 103% year over year.
Outlook
Moving ahead, the company noted that its performance in 2016 and strategic initiatives have positioned it for strong growth in 2017. Albemarle sees net sales in the band of $2.8 billion to $2.95 billion and adjusted earnings per share of between $4.00 and $4.25 for 2017. Adjusted EBITDA for the year is expected to be between $800 million and $840 million.
Price Performance
Albemarle’s shares have gained 64.4% over a year, outperforming the Zacks categorized Chemicals-Diversified industry’s gain of 28.5% over the same period, partly reflecting its forecast-topping earnings performance over the trailing four quarters.
Zacks Rank & Key Picks
Albemarle is a Zacks Rank #2 (Buy).
Other well-placed companies in the chemical space include Celanese Corporation (CE - Free Report) , Cabot Corporation (CBT - Free Report) and The Chemours Company (CC - Free Report) , all sporting a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Celanese has an expected long-term growth of 8.8%.
Cabot has an expected long-term growth of 12.1%.
Chemours has an expected long-term growth of 15.5%.
A Full-Blown Technological Breakthrough in the Making
Zacks’ Aggressive Growth Strategist Brian Bolan explores autonomous cars in our latest Special Report, Driverless Cars: Your Roadmap to Mega-Profits Today. In addition to who will be selling them and how the auto industry will be impacted, Brian reveals 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>